ciglitazone has been researched along with Ovarian Neoplasms in 6 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control." | 3.77 | Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. ( Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y, 2011) |
| "Both meloxicam and ciglitazone treatments significantly suppressed the growth of OVCAR-3 tumors xenotransplanted subcutaneously and significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared with controls." | 3.74 | Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. ( Futagami, M; Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y, 2007) |
| "Ciglitazone is a peroxisome proliferator-activated receptor γ (PPARγ) agonist and improves insulin sensitivity." | 1.40 | Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. ( Cho, CH; Ha, E; Kim, JY; Kwon, SY; Mun, KC; Shin, SJ, 2014) |
| "CGZ and TGZ cause a decrease in ovarian cancer cell proliferation that is PPARγ independent." | 1.37 | Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. ( Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SJ | 1 |
| Kim, JY | 1 |
| Kwon, SY | 1 |
| Mun, KC | 1 |
| Cho, CH | 1 |
| Ha, E | 1 |
| Bräutigam, K | 1 |
| Biernath-Wüpping, J | 1 |
| Bauerschlag, DO | 1 |
| von Kaisenberg, CS | 1 |
| Jonat, W | 1 |
| Maass, N | 1 |
| Arnold, N | 1 |
| Meinhold-Heerlein, I | 1 |
| Al-Alem, L | 1 |
| Southard, RC | 1 |
| Kilgore, MW | 1 |
| Curry, TE | 1 |
| Yokoyama, Y | 2 |
| Xin, B | 2 |
| Shigeto, T | 2 |
| Mizunuma, H | 2 |
| Vignati, S | 1 |
| Albertini, V | 1 |
| Rinaldi, A | 1 |
| Kwee, I | 1 |
| Riva, C | 1 |
| Oldrini, R | 1 |
| Capella, C | 1 |
| Bertoni, F | 1 |
| Carbone, GM | 1 |
| Catapano, CV | 1 |
| Futagami, M | 1 |
6 other studies available for ciglitazone and Ovarian Neoplasms
| Article | Year |
|---|---|
Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; beta Catenin; Cell Death; Cell Line, Tumor; Femal | 2014 |
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Chromans; | 2011 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian | 2011 |
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascites | 2011 |
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.
Topics: Cell Cycle; Cell Survival; Down-Regulation; Female; Gene Expression Profiling; Humans; Ligands; Ovar | 2006 |
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Topics: Animals; Apoptosis; Ascites; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2007 |